Key Highlights

  • 8.7 percent was the October 5, 2026 gain for Twist Bioscience (NASDAQ:TWST), which closed at USD 205.00 from USD 188.67 on Volume of about 3.2 million shares.
  • September 16, 2026 was when Twist agreed to Supply antibody data and services to Eli Lilly's TuneLab AI platform, with no financial terms disclosed for Twist Bioscience (NASDAQ:TWST).
  • USD 212 is the Guggenheim price target reported for Twist Bioscience (NASDAQ:TWST), up from USD 107, while Leerink reported USD 190 and UBS began coverage at Neutral with USD 144.
  • 27.3 times sales and an Operating Margin of negative 31.9 percent were reported for Twist Bioscience (NASDAQ:TWST), a reminder that the 2026 rally has outrun current profits and carries valuation risk.

The October 5 Move

Published market data show Twist Bioscience (NASDAQ:TWST) opening at USD 193.46, reaching USD 207.90 and closing at USD 205.00 on October 5, 2026, up 8.7 percent from USD 188.67. That compares with a close of USD 164.60 on September 22, a gain of about 25 percent in 10 sessions by simple arithmetic. The company did not appear to publish new news that day. Instead commentary tied the move to the Eli Lilly TuneLab agreement announced on September 16, 2026, work on AI-designed mini-binder proteins reported with Anthropic, and a series of analyst target increases. A stub reported a later 10.7 percent Reversal to USD 183.12, which could not be verified.

Why AI Data Deals Matter

Twist makes synthetic DNA and antibody libraries, so it can generate the laboratory data that AI drug discovery models need to train. Under the Lilly deal its wet-lab results feed into TuneLab models. Analysts reported that Leerink raised its target twice in September, with a USD 160 step on September 17 and a later USD 190, and Guggenheim more than doubled its target to USD 212. Ginkgo Bioworks (NYSE:DNA) made a similar data supply announcement on September 15, so investors are treating lab data suppliers as a theme. Reported quarterly Revenue was about USD 118 million with a gross margin near 52 percent, and the company has targeted adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.

Risks and What to Watch

The risks are valuation and losses. Trailing revenue of USD 431.80 million grew 19.2 percent, but net margin was negative 31.7 percent, and the shares trade at 27.3 times sales. A reported 52-week range of USD 23.30 to USD 219.71 shows how fast sentiment has moved, and a stock up several hundred percent this year can fall sharply if AI enthusiasm cools. Lilly terms are undisclosed. Watch the Federal Reserve minutes at 2:00 p.m. ET on October 7, rising Treasury yields, any new TuneLab style partners, and fiscal fourth quarter results, usually reported in November, with a date not confirmed. Technical support reported near USD 143 and resistance near USD 220 are not forecasts. Not Investment advice.

Where Things Stand

Twist Bioscience (NASDAQ:TWST) surged 8.7 percent to USD 205 on October 5, 2026 on momentum from its Lilly TuneLab agreement, AI-related deals and higher analyst targets, with no new company announcement found that day. The shares are far above their year-ago level, yet losses and a high sales multiple leave them exposed to any reversal in sentiment. Filings and the next Quarterly Report will show whether orders justify the multiple.